Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in preclinical studies.

Although COVID-19 vaccines did not increase risk for incidental thyroid disease, the first dose was associated with exacerbation of hypothyroidism. Vaccination against COVID-19 is associated with an ...

Newborns born to mothers diagnosed with COVID-19 infection during pregnancy exhibited increased prevalence and risk for respiratory distress syndrome, highlighting the importance of effective ...

Guillain-Barré Syndrome is an uncommon, rare neurological condition in which the immune system mistakenly attacks the body's ...

Cases of whooping cough have exploded to the highest rate in more than a decade with young children affected the most by the deadly infection.

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

‘The ‘mild’ days of Omicron are over’: How new COVID strains could double the 10k death toll ...

It is contagious in humans and is the cause of the coronavirus disease 2019 (COVID ... BA.2.86 are epitopes linked to immune escape from antibody recognition. Long Fung Chau and colleagues report ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

A live-updating map of novel coronavirus cases by zip code, courtesy of ESRI/JHU. Click on an area or use the search tool to enter a zip code. Use the + and - buttons to zoom in and out on the map.

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...